Ken Griffin Inventiva S.A. Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$10.73 - $14.85 $173,031 - $239,471	-16,126 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$13.0 - $15.67 $429 - $517	33 Added 0.21%	16,126 $219,000
Q1 2021 May 17, 2021	SELL	$12.55 - $19.0 $64,896 - $98,249	-5,171 Reduced 24.32%	16,093 $237,000
Q4 2020 Feb 16, 2021	BUY	$11.35 - $14.5 $241,346 - $308,328	21,264 New	21,264 $308,000

4.85M

Ticker IVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,134,200
Market Cap $110M
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company als...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.